SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?


To: quidditch who wrote (1485)1/12/2006 6:15:07 PM
From: software salesperson  Read Replies (1) | Respond to of 1834
 
It’s worth noting that lyons foresees the gnrh antagonist for endometriosis to be a billion/year drug, i.e. 7.5 m market, 2.5 m of whom have been diagnosed and on treatment, assuming ~ $ 3/ day and a 20-25% share. He believes that the drug has shown proof of concept already. Plus, there’s the bph market for men.

sales